Why Vitae Pharmaceuticals Inc's (VTAE) Post-Earnings Slide Could Be Just the Beginning

Vitae Pharmaceuticals Inc (VTAE) could continue to explore new lows if bullish analysts change their minds

Mar 4, 2016 at 10:46 AM
facebook twitter linkedin


Biotech stock Vitae Pharmaceuticals Inc (NASDAQ:VTAE) hit an all-time low of $4.15 this morning, and was last seen down 54.9% at $4.42, following the company's fourth-quarter earnings report. Vitae posted a smaller-than-forecast loss for the quarter, but revenue underwhelmed. A discouraging note from the analyst community is also weighing on the stock.

Specifically, Stifel -- which formerly rated VTAE a "buy" -- lowered its opinion to "hold," saying it doesn't expect to hear any good news regarding the company's autoimmune disorder drug when data from its latest trial is released later in the quarter. (Interestingly, the drug produced positive top-line results back in November.) Additionally, the brokerage expressed concern that the drugmaker closed enrollment for the drug trial at 34 patients when it was expected to enroll 60. 

This may be just the beginning of VTAE's struggles. Aside from Stifel, every analyst that covers the stock rates it a "strong buy," meaning there's potential for others to follow its bearish lead. Even more alarming is the biotech's consensus 12-month price target of $21.67 -- almost five times the current share price, leaving the door wide open for potential price-target cuts.

Elsewhere, it doesn't look like short sellers are going away anytime soon. Short interest increased another 8.6% during the two most recent reporting periods. The roughly 1.8 million VTAE shares now sold short represent close to 16% of the stock's float, and at average daily volumes, it'd take bears almost 18 sessions to buy back their bets. 

Pessimism seems apt given Vitae Pharmaceuticals Inc's (NASDAQ:VTAE) technical performance. In 2016 alone, the shares have lost more than three-fourths of their value. More negativity from analysts combined with additional pressure from emboldened short sellers could spell trouble for VTAE. 

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Best stocks for October and worst stocks for October
 


 


 
Special Offers from Schaeffer's Trading Partners